Beliefs and Adherence in Hypertension and Cardiovascular Protection

  • Amy Chan
  • Rob HorneEmail author
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)


Medication adherence is key to achieving good outcomes in hypertension and cardiovascular disease. However, adherence to preventive treatments remains poor with less than 50% of people adhering to treatment as prescribed. Many people do not even begin taking the medication, and even when treatment is initiated, early discontinuation is common. There have been many adherence interventions developed to promote adherence; however, the effectiveness of these have been limited. This chapter summarises the evidence to date on interventions to promote adherence and discusses the importance of approaching adherence from the individual patient perspective. A Perceptions and Practicalities Approach to designing and delivering interventions is then described, which outlines a pragmatic method for clinicians to adopt to encourage medication adherence. Explanations of how to implement this in practice, as well as factors to consider when designing adherence interventions, are discussed.


Adherence Medication Hypertension Cardiovascular Beliefs Health psychology Intervention Psychological models Perceptions and practicalities Outcomes 


  1. 1.
    Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Sabaté E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.Google Scholar
  3. 3.
    Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, Falvey H, Vincze G, Klungel OH, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin. 2008;24(1):121–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284–90.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882–7.e1.CrossRefPubMedGoogle Scholar
  6. 6.
    Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008;117(8):1028–36.CrossRefPubMedGoogle Scholar
  8. 8.
    Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Esposti LD, Saragoni S, Benemei S, Batacchi P, Geppetti P, Di Bari M, et al. Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients. Clinicoecon Outcomes Res. 2011;3:47–54.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598–605.CrossRefPubMedGoogle Scholar
  11. 11.
    De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014;78(4):684–98.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Dragomir A, Cote R, Roy L, Blais L, Lalonde L, Berard A, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48(5):418–25.CrossRefPubMedGoogle Scholar
  13. 13.
    Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med. 2013;126(4):357.e7–e27.CrossRefGoogle Scholar
  14. 14.
    Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;(11):CD000011.Google Scholar
  15. 15.
    Haynes RB, Sackett DL, Gibson ES, Taylor DW, Hackett BC, Roberts RS, et al. Improvement of medication compliance in uncontrolled hypertension. Lancet. 1976;1(7972):1265–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm. 2011;33(1):132–40.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Horne R, Weinman J, Barber N, Elliott R, Morgan M, Cribb A. Concordance, adherence and compliance in medicine taking: report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO). London: NCCSDO; 2005.Google Scholar
  18. 18.
    Nunes V, Neilson J, O’Flynn N, Calvert N, Kuntze S, Smithson H, et al. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. London: National Institute for Health and Clinical Excellence; 2009.Google Scholar
  19. 19.
    Conn VS, Ruppar TM, Chase JA, Enriquez M, Cooper PS. Interventions to improve medication adherence in hypertensive patients: systematic review and meta-analysis. Curr Hypertens Rep. 2015;17(12):94.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Cutrona SL, Choudhry NK, Fischer MA, Servi AD, Stedman M, Liberman JN, et al. Targeting cardiovascular medication adherence interventions. J Am Pharm Assoc. 2012;52(3):381–97.CrossRefGoogle Scholar
  21. 21.
    Becker MH, Maiman LA. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care. 1975;13(1):10–24.CrossRefPubMedGoogle Scholar
  22. 22.
    Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005;23(11):2101–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Shah NR, Hirsch AG, Zacker C, Wood GC, Schoenthaler A, Ogedegbe G, et al. Predictors of first-fill adherence for patients with hypertension. Am J Hypertens. 2009;22(4):392–6.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Marshall IJ, Wolfe CDA, McKevitt C. Lay perspectives on hypertension and drug adherence: systematic review of qualitative research. BMJ. 2012;345:e3953.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ross S, Walker A, MacLeod MJ. Patient compliance in hypertension: role of illness perceptions and treatment beliefs. J Hum Hypertens. 2004;18(9):607–13.CrossRefPubMedGoogle Scholar
  26. 26.
    Stack RJ, Elliott RA, Noyce PR, Bundy C. A qualitative exploration of multiple medicines beliefs in co-morbid diabetes and cardiovascular disease. Diabet Med. 2008;25(10):1204–10.CrossRefPubMedGoogle Scholar
  27. 27.
    Michie S, Johnston M, Francis J, Hardeman W, Eccles M. From theory to intervention: mapping theoretically derived behavioural determinants to behaviour change techniques. Appl Psychol. 2008;57(4):660–80.CrossRefGoogle Scholar
  28. 28.
    Piette JD, Heisler M, Horne R, Alexander GC. A conceptually based approach to understanding chronically ill patients’ responses to medication cost pressures. Soc Sci Med. 2006;62(4):846–57.CrossRefPubMedGoogle Scholar
  29. 29.
    Fogg BJ, editor. A behavior model for persuasive design. In: Proceedings of the 4th international conference on persuasive technology, ACM; 2009.Google Scholar
  30. 30.
    Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6(1):42.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Traylor AH, Schmittdiel JA, Uratsu CS, Mangione CM, Subramanian U. Adherence to cardiovascular disease medications: does patient-provider race/ethnicity and language concordance matter? J Gen Intern Med. 2010;25(11):1172–7.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Vervloet M, Linn AJ, Van Weert J, De Bakker DH, Bouvy ML, Van Dijk L. The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literature. J Am Med Inform Assoc. 2012;19(5):696–704.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1–24.CrossRefGoogle Scholar
  34. 34.
    Bloom BS. Daily regimen and compliance with treatment: fewer daily doses and drugs with fewer side effects improve compliance. BMJ. 2001;323(7314):647.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Marešová V, et al. Risk factors for nonadherence to antihypertensive treatment—novelty and significance. Hypertension. 2017;69(6):1113–20.CrossRefPubMedGoogle Scholar
  36. 36.
    Horne R, Chapman S, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013;8(12):e80633.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Horne R, Clatworthy J. Adherence to advice and treatment. Health psychology. 2nd ed. Chichester: British Psychological Society and Blackwell Publishing Ltd; 2010. p. 175–88.Google Scholar
  38. 38.
    Morgan M, Watkins CJ. Managing hypertension: beliefs and responses to medication among cultural groups. Sociol Health Illn. 1988;10(4):561–78.CrossRefGoogle Scholar
  39. 39.
    Andrade JP, Vilas-Boas F, Chagas H, Andrade M. Epidemiological aspects of adherence to the treatment of hypertension. Arq Bras Cardiol. 2002;79(4):380.CrossRefGoogle Scholar
  40. 40.
    Horne R, Faasse K, Cooper V, Diefenbach MA, Leventhal H, Leventhal E, et al. The perceived sensitivity to medicines (PSM) scale: an evaluation of validity and reliability. Br J Health Psychol. 2013;18(1):18–30.CrossRefPubMedGoogle Scholar
  41. 41.
    Heller MK, Chapman SC, Horne R. Beliefs about medication predict the misattribution of a common symptom as a medication side effect—evidence from an analogue online study. J Psychosom Res. 2015;79(6):519–29.CrossRefPubMedGoogle Scholar
  42. 42.
    Rief W, Bingel U, Schedlowski M, Enck P. Mechanisms involved in placebo and nocebo responses and implications for drug trials. Clin Pharmacol Therap. 2011;90(5):722–6.CrossRefGoogle Scholar
  43. 43.
    Rose LE, Kim MT, Dennison CR, Hill MN. The contexts of adherence for African Americans with high blood pressure. J Adv Nurs. 2000;32(3):587–94.CrossRefPubMedGoogle Scholar
  44. 44.
    Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy*. Am J Hypertens. 2006;19(11):1190–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Richardson MA, Simons-Morton B, Annegers JF. Effect of perceived barriers on compliance with antihypertensive medication. Health Educ Q. 1993;20(4):489–503.CrossRefPubMedGoogle Scholar
  46. 46.
    Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160(1):31–7.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Tedla YG, Bautista LE. Drug side effect symptoms and adherence to antihypertensive medication. Am J Hypertens. 2016;29(6):772–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Bovet P, Burnier M, Madeleine G, Waeber B, Paccaud F. Monitoring one-year compliance to antihypertension medication in the Seychelles. Bull World Health Organ. 2002;80(1):33–9.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814–22.PubMedGoogle Scholar
  50. 50.
    Boeni F, Spinatsch E, Suter K, Hersberger KE, Arnet I. Effect of drug reminder packaging on medication adherence: a systematic review revealing research gaps. Syst Rev. 2014;3(1):29.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Gollwitzer PM, Brandstätter V. Implementation intentions and effective goal pursuit. J Pers Soc Psychol. 1997;73(1):186.CrossRefGoogle Scholar
  52. 52.
    Lally P, Gardner B. Promoting habit formation. Health Psychol Rev. 2013;7(sup1):S137–S58.CrossRefGoogle Scholar
  53. 53.
    Cohen SM. Concept analysis of adherence in the context of cardiovascular risk reduction. Nurs Forum. 2009;44(1):25–36.CrossRefPubMedGoogle Scholar
  54. 54.
    Horne R, Parham R, Driscoll R, Robinson A. Patients’ attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(6):837–44.CrossRefPubMedGoogle Scholar
  55. 55.
    El Alili M, Vrijens B, Demonceau J, Evers SM, Hiligsmann M. A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. Br J Clin Pharmacol. 2016;82(1):268–79.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Horne R, Weinman J. The theoretical basis of concordance and issues for research. In: Bond C, editor. Concordance: a partnership in medicine-taking. London: Pharmaceutical Press; 2004.Google Scholar
  57. 57.
    Hamine S, Gerth-Guyette E, Faulx D, Green BB, Ginsburg AS. Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review. J Med Internet Res. 2015;17(2):e52.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Centre for Behavioural Medicine, Department of Practice and PolicyUCL School of Pharmacy, University College LondonLondonUK

Personalised recommendations